- Coordinator
- Uppsala Universitet, Sweden
- Runs
- 1 January 2024 to 31 December 2027
- Status
- Running
- EU funding
- €3.6m
- Total cost
- €3.6m
- Partners
- 8 organisations in 6 countries
- Type
- European Innovation Council
- Grant agreement
- 101130633
What the project is doing
In the project's own words, from its summary on CORDIS.
Currently, there are no vaccines against HIV (human immunodeficiency virus) and HSV (herpes simplex virus) infections. Condom, when used properly, are the most effective means of prophylaxis against viral transmission. However, there is a significant gender imbalance in condom use because women are not always in control over their use. In addition, women are at least twice as likely as men to contract sexually transmitted infections (STIs) from infected partners.
Several STIs, including HIV, are underdiagnosed due to asymptomatic infections and/or lack of testing facilities. This is particularly problematic for women from African countries, who are at high risk of contracting STIs but have poor access to testing facilities. Alternatives to condoms that use established antivirals for HIV prophylaxis come with issues such as antimicrobial resistance and low adherence in practice in high-risk groups.
There are also no means other than condoms for prophylaxis against HSV. Co-infection with HIV/HSV results in a vicious cycle of mutual facilitation, as individuals who are carriers of HSV have a three- to fourfold increased risk of contracting HIV. Inspired by nature, NatProLub develops a radically novel prophylactic approach to HIV and HSV prophylaxis through the use of lubricants. By targeting women, who are particularly at risk, NatProLub has a clear vision for a user-friendly, prophylactic product that can redress the gender imbalance in sexual health while offering a low risk of side effects and avoiding the risk of developing antimicrobial resistance.
The members of the NatProLub consortium have very strong backgrounds in relevant but complementary scientific disciplines that will contribute to the development of prophylactic lubricants for end users and have previous successful experience in managing large scientific projects, the creation of spin-off companies, and maintaining well-developed professional networks in academia, industry, and healthcare.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Uppsala Universitet | Uppsala | Sweden | Coordinator |
| Technische Universitaet Muenchen | Muenchen | Germany | Participant |
| Cirqle Biomedical Contraception Aps | Kobenhavn | Denmark | Participant |
| Commissariat a L Energie Atomique Et Aux Energies Alternatives | Paris | France | Participant |
| Universita Degli Studi Di Torino | Torino | Italy | Participant |
| Cellularis Biomodels Lda | Ilhavo | Portugal | Participant |
| Karolinska Institutet | Stockholm | Sweden | Participant |
| Kungliga Tekniska Hoegskolan | Stockholm | Sweden | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI